[Efficiency of the home intravenous antibiotics treatment in cystic fibrosis].
OBJECTIVE
The objective of our study was to determine the costs saving with the implementing of a home intravenous antibiotic treatment (HIVAT) program for patients with cystic fibrosis and to compare it with the conventional system (inpatient).


METHODS
Consecutive patients in an adults cystic fibrosis unit were selected who received some days of HIVAT, between January 2002 and December 2004. For the analysis of costs saving of the HIVAT, we used the difference between the total costs of the avoided stay days and the costs generated by the domiciliary therapy (drugs, expendable equipment) and by the ambulatory medicine unit in case the patients were not hospitalized. All patients received a therapy with an intravenous antibiotic for a minimum of 14 days. All these data were provided by the accounting service of the hospital with the aid management Clinical Financier Program (GECLIF).


RESULTS
22 patients with cystic fibrosis needed 85 intravenous antibiotics treatments during the 3 years of the study, of which: 43 cycles were completely domiciliary, 14 inpatient and 28 were combined (hospital and home). The 71 cycles of HIVAT originated 909 days at home, with an average (standard deviation) of 12.80 (4.18) days and 43 treatments in ambulatory medicine unit. The home antibiotic treatments that originated greater cost (3,964.34 Euro) was meropenem (1 g/6 h) i.v. with linezolid (600 mg/12 h) via oral combination during 14 days, and in second place the association of ceftazidime, tobramycine and linezolid, whose cost in cycle of 14 days was of 2464.84 Euro. The average saving cost in the 3 years of study was of 2,647.29 Euro by each cycle of HIVAT and global 197,689.78 Euro.


CONCLUSIONS
HIVAT obtained important sanitary costs saving and this was greater every year, not due to the increase of days at home, but due to the rising cost per day of hospital stays every new year.
Girón
Rosa María
RM
Servicio de Neumología. Hospital Universitario de la Princesa. Madrid. España. med002861@nacom.es
Cisneros
Carolina
C
Nakeeb
Zaid Al
ZA
Hoyos
Nieves
N
Martínez
Concha
C
Ancochea
Julio
J
D000328:Adult; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000191:economics; D005260:Female; D018718:Home Infusion Therapy / Q000191:economics; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents